Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes Plc EPS Soars Past Forecasts
10:37am, Wednesday, 12'th Feb 2025
Alkermes (ALKS 2.50%), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported ro
Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Wednesday, 12'th Feb 2025
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Str
Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates
09:40am, Wednesday, 12'th Feb 2025
Alkermes (ALKS) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.48 per share a year ago.
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
07:00am, Wednesday, 12'th Feb 2025
— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million
What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings
10:20am, Monday, 10'th Feb 2025
Beyond analysts' top -and-bottom-line estimates for Alkermes (ALKS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
04:00pm, Wednesday, 05'th Feb 2025
DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:00pm, Thursday, 02'nd Jan 2025
DUBLIN , Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. M
Alkermes to Participate in Upcoming Investor Conferences
04:00pm, Monday, 25'th Nov 2024
DUBLIN , Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx Conference
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
09:58am, Sunday, 24'th Nov 2024
Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy
Alkermes to Participate in Two Upcoming Investor Conferences
04:00pm, Monday, 11'th Nov 2024
DUBLIN , Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
07:00am, Thursday, 07'th Nov 2024
– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and T
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
11:11am, Friday, 25'th Oct 2024
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year.
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
01:04pm, Thursday, 24'th Oct 2024
Alkermes plc (NASDAQ:ALKS ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
12:06pm, Thursday, 24'th Oct 2024
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
09:11am, Thursday, 24'th Oct 2024
Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago.
